Navigation Links
Karolinska Development Introduces New Concept for Development of its Dermatology and Wound Healing Portfolio
Date:9/9/2009

STOCKHOLM, September 9 /PRNewswire/ -- Karolinska Development (publ) have announced the formation of Pergamum AB, a company that will commercialize its dermatology and wound healing opportunities as associated business units within one company. Karolinska Development has transferred all of its holdings from its five dermatology and wound healing companies to Pergamum AB, owning 64% of the new company.

"This is a new initiative from Karolinska Development as part of our overall strategy to maximize value appreciation within our portfolio," stated Conny Bogentoft, CEO of Karolinska Development. "We have an exciting group of technologies in this area and we expect the new corporate structure to both reduce costs and speed up development times. It also offers considerable advantages when seeking exit opportunities. Pergamum will be able to represent several or all of the development projects when discussing sales or licensing opportunities with pharma companies. We are not aware of any other similar situation within the industry," added Dr Bogentoft.

Pergamum's development projects currently cover improved wound healing and reduced scar formation, healing hard-to-heal-wounds, the prevention of bacterial and fungal infections, atopic dermatitis and infected wounds and burns.

Magnus Precht, CEO of Pergamum AB, said, "There is a good balance across the business units and we already have three projects undergoing clinical trials. What makes Pergamum different is that we provide each of our individual businesses with access to technical skills and key competencies in an extremely resource-efficient way. This is something that other companies at similar stages of development simply cannot do. In addition, by focusing on related fields we are able to continually acquire and share specialist knowledge that will benefit development over the long term."

Pergamum CEO Magnus Precht will present Pergamum at the Rodman & Renshaw Annual Global Investment Conference in New York September 9-11, 2009 and will be available for one-on-one meetings with investors and potential partners during the conference.

Pergamum's other two owners are Ostersjostiftelsen (The Foundation for Baltic and East European Studies) and Midroc New Technology.

About Karolinska Development:

Managing one of the largest portfolios of life science research companies in Europe, Karolinska Development

AB is a new type of company focused on filling the innovation gap within the pharmaceutical industry. Using a unique, highly cost-effective model Karolinska Development commercializes internationally renowned life science innovations, helping to deliver the medical products of the future.

    For more information please contact:

    Conny Bogentoft, CEO, Karolinska Development AB
    Cell phone +46-70-668-61-43
    info@karolinskadevelopment.com
   http://www.karolinskadevelopment.com

    Magnus Precht, CEO, Pergamum AB
    European mobile phone: +46-73-515-7450
    US cell phone: +1-817-312-7277
    magnus.precht@pergamum.com
   http://www.pergamum.com



'/>"/>
SOURCE Karolinska Development AB
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Karolinska Institutet Awards Honorary Degree to Feinstein Institute CEO Kevin J. Tracey, MD
2. Karolinska Development Invests in EvoStem Finland Oy
3. Dr. Henry Barnett becomes first person outside Europe to receive Karolinska Stroke Award
4. The Feinstein to collaborate with Swedens Karolinska Institute
5. 3 new honorary doctors at Karolinska Institutet
6. Karolinska Institutets Pedersen to receive GSAs 2007 Distinguished Career Award
7. Special Autism Issue Published by the College of Optometrists in Vision Development
8. Cepheid Announces Accelerated Development of Flu A Panel Test
9. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
10. Vaxart Awarded NIH Grant to Support Development of Orally-Delivered H5N1 Avian Influenza Vaccine
11. Founder of Curidium Launches Elixior, an Advisory Company Focused on the Development and Growth of Innovative Personalized Medicine Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of travel therapy ... MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason ... extensive financial and operational leadership experience to Advanced Inc. He began his career in ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of ... of an injury, patients must find the one that works for them. When an ... created a machine that worked and decided to share it with others. , He ...
(Date:12/2/2016)... ... December 02, 2016 , ... CloudLIMS.com, a class-leading provider of ... Lite. CloudLIMS Lite helps biobanks, clinical, research and testing laboratories keep track of ... new version is a faster and a more efficient product, allowing batch processing ...
(Date:12/2/2016)... ... 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, Texas, ... Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in 1934 ... details line up exactly with Bible Prophecy – a protected way for those who ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... & Author of Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein ... Hour Power of Water, Global Climate Change and Your Health radio program syndicated ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , December 2, 2016 ... Awards Committee honored excellence in research, development and innovation ... The gala dinner was held in the presence of ... the Russian Federation , Natalia Sanina, ... Mikhail Murashko , Head of Roszdravnadzor, National Service ...
(Date:12/2/2016)... 2, 2016  Maxor National Pharmacy Services, LLC ("Maxor"), today ... Inc. ("PSI").  The combination of Texas -based ... -based PSI bring together both company,s clinical expertise and high-touch ... an industry-leading specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... Dec. 2, 2016 Boston Scientific Corporation (NYSE: ... to acquire certain manufacturing assets and capabilities of the ... advanced biological tissue business, as well as a 15% ... million in cash. The Neovasc advanced biological tissue business ... Boston Scientific Lotus™ Valve System. * Upon completion ...
Breaking Medicine Technology: